- Home
- CLGN vs CASI Comparison
CLGN vs CASI Comparison
Compare CLGN & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- CASI
- Stock Information
- Founded
- CLGN 2004
- CASI 1991
- Country
- CLGN Israel
- CASI China
- Employees
- CLGN N/A
- CASI N/A
- Industry
- CLGN Industrial Specialties
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- CASI Health Care
- Exchange
- CLGN Nasdaq
- CASI Nasdaq
- Market Cap
- CLGN 33.8M
- CASI 35.8M
- IPO Year
- CLGN N/A
- CASI 1996
- Fundamental
- Price
- CLGN N/A
- CASI $1.85
- Analyst Decision
- CLGN Strong Buy
- CASI Strong Buy
- Analyst Count
- CLGN 2
- CASI 1
- Target Price
- CLGN $11.50
- CASI $4.00
- AVG Volume (30 Days)
- CLGN 257.5K
- CASI 298.8K
- Earning Date
- CLGN 11-26-2025
- CASI 11-13-2025
- Dividend Yield
- CLGN N/A
- CASI N/A
- EPS Growth
- CLGN N/A
- CASI N/A
- EPS
- CLGN N/A
- CASI N/A
- Revenue
- CLGN $2,402,000.00
- CASI $31,564,000.00
- Revenue This Year
- CLGN $1,617.28
- CASI N/A
- Revenue Next Year
- CLGN $83.54
- CASI N/A
- P/E Ratio
- CLGN N/A
- CASI N/A
- Revenue Growth
- CLGN 248.62
- CASI 36.64
- 52 Week Low
- CLGN $1.31
- CASI $1.09
- 52 Week High
- CLGN $4.99
- CASI $6.50
- Technical
- Relative Strength Index (RSI)
- CLGN 45.87
- CASI 49.66
- Support Level
- CLGN $2.11
- CASI $1.75
- Resistance Level
- CLGN $2.44
- CASI $2.13
- Average True Range (ATR)
- CLGN 0.22
- CASI 0.20
- MACD
- CLGN -0.03
- CASI 0.02
- Stochastic Oscillator
- CLGN 23.36
- CASI 69.57
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.